Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Clinical trial NCT05718323 · RECRUITING
Trial details
- NCT number
- NCT05718323
- Sponsor
- ETOP IBCSG Partners Foundation
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-20
- Primary completion
- 2026-12-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.